Trial reportThe Journal of infectious diseases2017
Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana.
Trial report in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 1 synthesis or guideline pooled it, 308 citations in OpenAlex.
- Interventions to improve oral vaccine performance: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2019Pooled it
- Gut Prevotella stercorea associates with protection against infection in rural African children.Nature communications · 2025Trial
- Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BB.Nature communications · 2025Trial
- Skin exposure to soil microbiota elicits changes in cell-mediated immunity to pneumococcal vaccine.Scientific reports · 2024Trial
- Trial
- Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants.Nature communications · 2021Trial
- The fecal microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants.Vaccine · 2021Trial
- Trial
- Enteropathogens and Rotavirus Vaccine Immunogenicity in a Cluster Randomized Trial of Improved Water, Sanitation and Hygiene in Rural Zimbabwe.The Pediatric infectious disease journal · 2019Trial
- Trial
- A phase I trial of WRSS1, aHuman vaccines & immunotherapeutics · 2019Trial
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.PloS one · 2019Trial
- Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries.Epidemiology (Cambridge, Mass.) · 2018Trial
- Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial.Cell host & microbe · 2018Trial
- Klebsiella-dominant gut communities are associated with impeded oral rotavirus vaccine response in infants.Nature communications · 2026Article
- Gut microbiome-enteric virus interactions: mechanisms, clinical implications, and translational directions.Journal of gastroenterology · 2026Review
- Why does rotavirus vaccine effectiveness vary around the globe?PLoS pathogens · 2026Review
- Early-life gut microbiome composition and rotavirus vaccine-induced IgA responses in U.S. infants: a longitudinal cohort study.EBioMedicine · 2026Article
- A Double-Edged Sword: Breast Milk-Derived Maternal Antibodies and Infant Vaccine Responses: A Narrative Review.Vaccines · 2026Review
- Impact of Early-Life Antibiotic Exposure on Gut Microbiome and Vaccine Immunogenicity in Infants: A Narrative Review.Journal of clinical medicine · 2026Review
147 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRotavirus (RV) is the leading cause of diarrhea-related death in children worldwide and 95% of RV-associated deaths occur in Africa and Asia where RV vaccines (RVVs) have lower efficacy. We hypothesize that differences in intestinal microbiome composition correlate with the decreased RVV efficacy observed in poor settings.
methodsWe conducted a nested, case-control study comparing prevaccination, fecal microbiome compositions between 6-week old, matched RVV responders and nonresponders in rural Ghana. These infants' microbiomes were then compared with 154 age-matched, healthy Dutch infants' microbiomes, assumed to be RVV responders. Fecal microbiome analysis was performed in all groups using the Human Intestinal Tract Chip.
resultsWe analyzed findings in 78 Ghanaian infants, including 39 RVV responder and nonresponder pairs. The overall microbiome composition was significantly different between RVV responders and nonresponders (FDR, 0.12), and Ghanaian responders were more similar to Dutch infants than nonresponders (P = .002). RVV response correlated with an increased abundance of Streptococcus bovis and a decreased abundance of the Bacteroidetes phylum in comparisons between both Ghanaian RVV responders and nonresponders (FDR, 0.008 vs 0.003) and Dutch infants and Ghanaian nonresponders (FDR, 0.002 vs 0.009).
conclusionsThe intestinal microbiome composition correlates significantly with RVV immunogenicity and may contribute to the diminished RVV immunogenicity observed in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.